Protara Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2013 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Protara Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2013 to Q3 2024.
  • Protara Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$11.2M, a 13.8% decline year-over-year.
  • Protara Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$42M, a 39.2% increase year-over-year.
  • Protara Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$40.4M, a 38.7% increase from 2022.
  • Protara Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$66M, a 39.6% decline from 2021.
  • Protara Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$47.3M, a 39.1% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$42M -$11.2M -$1.36M -13.8% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 -$40.7M -$9.51M +$1.78M +15.8% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-12
Q1 2024 -$42.5M -$11.1M -$2.05M -22.7% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-12
Q4 2023 -$40.4M -$10.2M +$28.7M +73.8% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-13
Q3 2023 -$69.2M -$9.86M -$2.17M -28.2% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 -$67M -$11.3M -$2.76M -32.3% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-12
Q1 2023 -$64.2M -$9.05M +$1.71M +15.9% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-12
Q4 2022 -$66M -$39M -$28.7M -281% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-13
Q3 2022 -$37.2M -$7.69M +$3.09M +28.6% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-03
Q2 2022 -$40.3M -$8.54M +$4.24M +33.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-03
Q1 2022 -$44.5M -$10.8M +$2.71M +20.1% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-03
Q4 2021 -$47.3M -$10.2M -$1.42M -16.1% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-08
Q3 2021 -$45.8M -$10.8M -$2.81M -35.2% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$43M -$12.8M -$5.64M -79% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-03
Q1 2021 -$37.4M -$13.5M -$3.41M -33.8% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-03
Q4 2020 -$34M -$8.81M -$6.29M -250% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-09
Q3 2020 -$27.7M -$7.97M -$5.62M -239% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$22.1M -$7.14M -$5.71M -400% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-04
Q1 2020 -$16.4M -$10.1M -$8.53M -558% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-04
Q4 2019 -$7.83M -$2.52M +$2.74M +52.1% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-11
Q3 2019 -$10.6M -$2.35M +$2.16M +47.8% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 -$12.7M -$1.43M +$3.45M +70.7% Apr 1, 2019 Jun 30, 2019 10-Q 2020-07-31
Q1 2019 -$16.2M -$1.53M +$4.55M +74.9% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-13
Q4 2018 -$20.7M -$5.26M +$292K +5.26% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-20
Q3 2018 -$21M -$4.51M +$7.8M +63.4% Jul 1, 2018 Sep 30, 2018 10-Q 2019-10-31
Q2 2018 -$28.8M -$4.88M +$729K +13% Apr 1, 2018 Jun 30, 2018 10-Q 2019-10-31
Q1 2018 -$29.5M -$6.08M +$417K +6.42% Jan 1, 2018 Mar 31, 2018 10-Q 2019-10-31
Q4 2017 -$30M -$5.55M +$1.41M +20.3% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-13
Q3 2017 -$31.4M -$12.3M -$5.2M -73.2% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-07
Q2 2017 -$26.2M -$5.61M +$2.3M +29.1% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-07
Q1 2017 -$28.5M -$6.5M +$54K +0.82% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-09
Q4 2016 -$28.5M -$6.96M -$620K -9.78% Oct 1, 2016 Dec 31, 2016 10-K 2019-03-13
Q3 2016 -$27.9M -$7.11M -$1.72M -32% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-07
Q2 2016 -$26.2M -$7.91M -$2.83M -55.9% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-07
Q1 2016 -$23.3M -$6.55M -$1.97M -43.1% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-10
Q4 2015 -$21.4M -$6.34M -$13.6M -188% Oct 1, 2015 Dec 31, 2015 10-K 2018-03-14
Q3 2015 -$7.8M -$5.38M -$202K -3.9% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-07
Q2 2015 -$7.6M -$5.07M -$2.51M -97.9% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-08
Q1 2015 -$5.09M -$4.58M -$1.75M -61.8% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-09
Q4 2014 -$3.34M $7.23M +$9.63M Oct 1, 2014 Dec 31, 2014 10-K 2016-03-14
Q3 2014 -$13M -$5.18M -$3.08M -146% Jul 1, 2014 Sep 30, 2014 10-K 2016-03-14
Q2 2014 -$9.89M -$2.56M -$1.02M -65.7% Apr 1, 2014 Jun 30, 2014 10-K 2016-03-14
Q1 2014 -$8.88M -$2.83M -$966K -51.8% Jan 1, 2014 Mar 31, 2014 10-K 2016-03-14
Q4 2013 -$7.91M -$2.4M Oct 1, 2013 Dec 31, 2013 10-K 2015-03-20
Q3 2013 -$2.1M Jul 1, 2013 Sep 30, 2013 10-K 2015-03-20
Q2 2013 -$1.55M Apr 1, 2013 Jun 30, 2013 10-K 2015-03-20
Q1 2013 -$1.87M Jan 1, 2013 Mar 31, 2013 10-K 2015-03-20
* An asterisk sign (*) next to the value indicates that the value is likely invalid.